跳至主要内容
临床试验/NCT04961164
NCT04961164已完成不适用

A Randomized Double-Blind Cross-over Trial to Study the Effects of Resistant Starch Prebiotic Effects in Chronic Kidney Disease (ReSPECKD)

University of Manitoba4 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2022年9月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
52
试验地点
4
主要终点
Change in blood uremic toxin, indoxyl sulphate, between treatments

研究概览

简要总结

In patients with Chronic Kidney Disease (CKD), there is a buildup of nitrogenous uremic toxins of gut microbiome origin, which can contribute to uremic symptoms, reduced quality of life, and earlier progression to dialysis. The goal of this project is to investigate whether the consumption of resistant potato starch (RPS) as an adjunctive therapy to current standard of CKD care will reduce uremic toxins and symptoms by altering the gut microbiota in patients with CKD.

详细描述

Participants will consent to follow a 18-week study regimen. Participants will receive 2 sachets per day containing either 15 grams of RPS or 15 grams corn starch. The powder in the sachets will be mixed in water and consumed, one sachet in the morning and one before bed. Participants will be instructed to consume the investigational product at least 2 hours prior to or after taking any medication.

For the first two weeks, all participants will go through a run-in period, where they will receive the corn starch. During weeks 3 to 8 (period 1) participants will receive either RPS or cornstarch. The first treatment received will be determined by randomization procedures. During weeks 9 to 12, all participants will undergo a washout period where they will consume cornstarch. During weeks 13 and 18 (period 2), participants will receive the treatment they did not previously consume.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant is willing and able to give informed consent for participation in the trial.
  • Participant has the ability to speak and read English.
  • Male or Female, aged 18 years or above. Females of child-bearing potential must agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.
  • Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m^2 for the past 3 months
  • In the Investigator's opinion, participant is able and willing to comply with all trial requirements.

排除标准

  • The participant is cognitively impaired and cannot give consent or participate in the group program
  • The participant has an existing relationship with the research team, such as supervisory relationship (student, employee) or familial relationship (child, spouse, etc)
  • Participants who indicate that they cannot consume study treatments.
  • Participants who indicates they are allergic to potatoes or corn
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
  • History of renal transplant, ongoing dialysis, use of antibiotics (last 3-months), bowel diseases, cancer, surgically removed bowel, or any gastrointestinal surgery (e.g. intestinal resection, gastric bypass, colorectal surgery)
  • Inability to consume treatment due to swallowing or GI issues and inability to obtain written informed consent.
  • Participating in another interventional trial that could influence the intervention or outcome of this trial.
  • Participants with uncontrolled diabetes with a hemoglobin A1C > 10%.
  • Participants who consume probiotic supplements.
  • Participants with abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, appendicitis, a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative prod.
  • Participants with severe anemia (hemoglobin less than 70).
  • Participants taking medications which inhibit peristaltic movement (e.g. opioids,loperamide).
  • Participants taking other fiber supplements or able to maintain high fiber/adequate fiber intake through diet.

研究组 & 干预措施

Resistant Potato Starch

Experimental

15g RPS mixed with water will be consumed twice per day during intervention

干预措施: Resistant Potato Starch, Corn Starch (Dietary Supplement)

Corn Starch

Placebo Comparator

15 g corn starch mixed with water will be consumed twice per day during intervention

干预措施: Corn Starch, Resistant Potato Starch (Dietary Supplement)

结局指标

主要结局

Change in blood uremic toxin, indoxyl sulphate, between treatments

时间窗: between endpoints of each experimental period (week 8 to week 18)

Change in indoxyl sulphate concentrations in serum

Change in blood uremic toxin, p-cresyl sulphate, between treatments

时间窗: between endpoints of each experimental period (week 8 to week 18)

Change in p-cresyl sulphate concentrations in serum

次要结局

  • Change in differential abundance in the gut microbiome between treatments(between endpoints of each experimental period (week 8 to week 18))
  • Change in symptoms score using the Edmonton Symptom Assessment Scale between treatments(between endpoints of each experimental period (week 8 to week 18))
  • Change in alpha diversity of the gut microbiome between treatments(between endpoints of each experimental period (week 8 to week 18))
  • Change in beta diversity of the gut microbiome between treatments(between endpoints of each experimental period (week 8 to week 18))
  • Change in quality of life of participants between treatments(between endpoints of each experimental period (week 8 to week 18))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dylan MacKay. PhD

Assistant Professor

University of Manitoba

研究点 (4)

Loading locations...

相似试验

Resistant Starch Prebiotic Effects in Chronic Kidney... | 临床试验